| Document |
Document Title |
|
WO/2020/157474A1 |
The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of ...
|
|
WO/2020/156106A1 |
Heterocyclic aryl formamides or a salt thereof, a preparation method, a weeding composition, and an application. The structural formula of the heterocyclic aryl formamide compound or the salt thereof is as shown in formula I, and the com...
|
|
WO/2020/152361A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2020/147740A1 |
Disclosed are triazole compounds, and a preparation method thereof and use. The triazole compounds in the present invention have good LPAR1 antagonistic activity and selectivity, low toxicity, and good metabolic stability, and can be use...
|
|
WO/2020/148403A1 |
The present invention is directed to 5-membered heteroaryl compounds containing a hydroxamate moiety of Formula I, pharmaceutically acceptable salts or solvates thereof, and their use as sensitizers for chemotherapy of malignant tumors.
|
|
WO/2020/139012A1 |
The present invention relates to a 18F-labeled compound for diagnosing prostate cancer and a use thereof. The carboxylic acid-introduced compound of the present invention forms strong ion-pair bonds (salt-bridge interactions) with argini...
|
|
WO/2020/134104A1 |
Provided is a preparation method for prothioconazole, comprising the following steps: A) carrying out a chlorination cyclization reaction of a compound represented by formula I to obtain a compound represented by formula II; B) conductin...
|
|
WO/2020/137819A1 |
Provided is a UV absorbent that has excellent light resistance or heat resistance, and excellent light resistance and heat resistance, i.e., durability, and that efficiently absorbs hazardous light in a wavelength region of 380-400 nm an...
|
|
WO/2020/133411A1 |
The present invention provides a preparation method for Efinaconazole, comprising the following steps: in the presence of bromide and base, subjecting (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1H-1,2,4-triazol
e-1-yl)methyl]ethylene ox...
|
|
WO/2020/132471A1 |
Provided herein are various salts, including tris(hydroxymethyl)aminomethane salts and sodium salts, as well as various crystalline forms of the compound represented by the structural formula: Also provided are pharmaceutical composition...
|
|
WO/2020/130214A1 |
The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at the terminal amine group thereof and a use thereof.
|
|
WO/2020/125776A1 |
Disclosed are a process route of a compound of formula (IV), a crystal form and a preparation method therefor. Also disclosed is an application of the crystal form in preparation of drugs for treating diseases associated with SSAO.
|
|
WO/2020/127685A1 |
The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositio...
|
|
WO/2020/121261A1 |
The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their ...
|
|
WO/2020/120994A1 |
The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurol...
|
|
WO/2020/118361A1 |
Ocular lenses having UV absorbing properties are disclosed. The ocular lens comprises a hydrogel polymer comprising polymerised residues derived from a polymerisable UV absorber of formula (I): U-L-Py (I) wherein: U is a UV absorbing moi...
|
|
WO/2020/117794A1 |
Compounds as exemplified by compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.
|
|
WO/2020/118139A1 |
Disclosed are compounds of the formulas (I), (II), and (II): which are A1 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein Y, R1‑R6, R10‑R15, and R20â...
|
|
WO/2020/112605A1 |
Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful for treating chronic bacterial infections. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention and a pha...
|
|
WO/2020/106780A1 |
Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene car...
|
|
WO/2020/104657A1 |
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment...
|
|
WO/2020/102506A1 |
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver ...
|
|
WO/2020/099645A1 |
The present invention relates to new compounds that act as inhibitors of metallo-betalactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of...
|
|
WO/2020/097012A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein A, Q, R1, R2, R3, R4, W and Y are as defined in the disclosure. Also disclosed are compositions containing...
|
|
WO/2020/092401A1 |
The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processe...
|
|
WO/2020/083971A2 |
The present invention relates to novel compounds of general formula (I) with A being A1 or A2, and in which T, X, Y, Ro, R1, R10 and R11 are as defined herein, methods of preparing said compounds, intermediate compounds useful for prepar...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/080979A1 |
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...
|
|
WO/2020/077197A1 |
The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
|
|
WO/2020/072008A1 |
The object of the present invention is to provide a pharmaceutical composition comprising solid dispersion of selinexor, having enhanced bioavailability and improved dissolution properties. In accordance with the invention, solid dispers...
|
|
WO/2020/063756A1 |
A novel triazole compound of the formula (IV) is provided, it can be used in agriculture, wherein R1 is cyclopropyl and the like; X is -CH2-and the like; each of R4 and R6 is independently hydrogen, fluorine, chlorine, CH3-, etc.; each o...
|
|
WO/2020/057604A1 |
A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
|
|
WO/2020/055507A1 |
Aprotic-protic ionic salt (APS) compositions and methods of using aprotic-protic ionic salt compositions to stabilize nucleic acids at ambient temperatures are provided. Certain aspects provide aprotic-protic ionic salt compositions for ...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/051260A1 |
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treatin...
|
|
WO/2020/043866A1 |
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
|
|
WO/2020/046382A1 |
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utili...
|
|
WO/2020/043831A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compound...
|
|
WO/2020/041556A1 |
The present invention relates to the discovery of novel N-(substituted)-1H-1,2,4-triazole-3-carboxamide compounds capable of inhibiting DksA activity in a bacteria cell. In certain embodiments, the compounds are capable of killing or wea...
|
|
WO/2020/036134A1 |
The present invention provides a 5-(1,2,4-triazole-5-yl) benzoic acid amide derivative with a superior harmful organism control effect or a salt thereof, and a harmful organism control agent and a manufacturing intermediate that include ...
|
|
WO/2020/036133A1 |
The present invention addresses the problem of providing a superior harmful organism control agent. Provided are the 3-(1H-1,2,4-triazole-1-yl) benzoic acid amide derivative shown in general formula [I] or an agrochemically permissible s...
|
|
WO/2020/010309A9 |
The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating ...
|
|
WO/2020/020851A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/020849A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/021032A1 |
The present invention relates to compounds of the generation (n) dendrimer type or the salts thereof, comprising: a central unit of valency 3 having formula (I), (n-1) inner generation layers consisting of repeat units having formula (II...
|
|
WO/2020/020850A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/018613A1 |
Provided herein are compounds of Formula I, Formula II Formula III which are useful in labeling tissues in a subject (e.g., PET imaging of a subject), for treatment of cancer, and/or for preparing a medicament. Also provided are compound...
|
|
WO/2020/018788A1 |
Disclosed are bifunctional compounds, pharmaceutical compositions containing them, and methods of making and using them to treat diseases and disorders characterized by aberrant protein activity wherein the protein is targeted for degrad...
|
|
WO/2020/011922A1 |
The present invention relates to certain dithiocarbamate compounds of formula (I) comprising a nitrogen containing heterocyclic ring, and exhibiting strong absorption in the visible range of the light spectrum. The compounds of the inven...
|
